Swedish Orphan Biovitrum Investor Relations Material
Latest events
Q1 2024
Swedish Orphan Biovitrum
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Swedish Orphan Biovitrum
Access all reports
Segment Data
Access more data
Revenue by
Business area
Haematology
Immunology
Specialty Care
Expenses by
Financials
Swedish Orphan Biovitrum AB, an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company operates through three segments: Haemophilia & Hereditary Diseases, Inflammation & Immunology, and Other. It offers Alprolix for hemophilia B; Elocta to treat hemophilia A; Doptelet for thrombocytopenia; Kineret for rheumatoid arthritis; Thiola for cystinuria; Xultophy Cartridge that is used with Flexpen for treatment of diabetes; and Velphoro for hyperphosphatemia.
Key slides for Swedish Orphan Biovitrum
Q2 2023
Swedish Orphan Biovitrum
Q4 2023
Swedish Orphan Biovitrum
Latest articles
Kevin Plank and the Rise of Under Armour
Dive into the story of Under Armour and its founder Kevin Plank, highlighting both successes and mistakes.
30 Apr 2024
Sergey Brin's Role in Shaping the Tech World
Explore Sergei Brin's journey from a Moscow immigrant to co-founding Google, detailing key developments and Alphabet's creation.
29 Apr 2024
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden